Drying Technologies for mRNA-LNPs: Freeze-Drying and Beyond

Lipid nanoparticles (LNPs) have enabled clinical use of nucleic acid medicines, including mRNA vaccines and an siRNA therapy. Yet many mRNA-LNP products depend on tightly controlled, low-temperature storage, which complicates distribution and access. In their review, Zhen et al. examine freeze-drying and other approaches to produce more stable solid forms of nucleic acid-LNPs. Their central message is that drying can help address storage constraints, but success depends on protecting both the particle and its nucleic acid cargo through processing, storage, and reconstitution.

Study Background and Research Question

Nucleic acid therapeutics have grown into a major drug class, but nucleic acids face delivery barriers and can be vulnerable to degradation. LNPs help solve the delivery problem: ionizable lipids support particle assembly with other lipids, associate with negatively charged nucleic acids, and contribute to delivery into cells. Clinical progress with mRNA vaccines and siRNA-LNPs has made this carrier platform especially important.

Formulation performance is only part of the development challenge. A liquid LNP product must remain suitable during storage and transport, and cold-chain dependence can complicate broad distribution. Drying offers a possible route to a solid product with improved storage stability. However, removing water is not a simple preservation step: processing can affect particle structure, cargo integrity, redispersion, and biological activity. The review therefore asks how drying technologies can be applied to mRNA-LNPs and related nucleic acid-LNPs, what stresses or limitations need consideration, and which approaches might fit different products and routes of administration.

Key Innovation from the Reference Study

The paper’s contribution is a comparative synthesis rather than a single new formulation or drying experiment. It brings together discussion of mRNA-LNP stability, freeze-drying development, processing challenges, and approaches intended to maintain stability during drying and subsequent storage. It also widens the discussion beyond mRNA to include siRNA, self-amplifying RNA (saRNA), circular RNA (circRNA), plasmid DNA (pDNA), microRNA, and CRISPR-related systems.

That breadth matters because “nucleic acid-LNP” does not describe one interchangeable payload. Cargoes differ in molecular structure and, as the authors emphasize, those structural differences can influence drying behavior. The review treats cargo identity as a design consideration rather than assuming that a successful mRNA approach will transfer unchanged to siRNA, circRNA, or a gene-editing system. It also compares conventional freeze-drying with alternative methods, including continuous freeze-drying based on spin-freezing, thin-film freeze-drying, spray freeze-drying, spray drying, and alcohol dilution freeze-drying. This provides a technology landscape for researchers considering not just whether to dry an LNP, but which process may be compatible with its intended use.

Methods and Experimental Design Insights

As a review, the article does not report a new, unified experimental protocol or head-to-head dataset. Instead, it organizes prior work around intrinsic stability, the status of freeze-drying, potential process challenges, and stabilization strategies. Its comparisons of nucleic acid classes and drying technologies are best read as a framework for experimental design, not as evidence that one method is universally superior.

For development studies, this framework suggests evaluating the whole product lifecycle. Researchers can characterize the liquid formulation before drying, assess the dried material, and then test the reconstituted product. Relevant questions include whether the particles redisperse consistently, whether the nucleic acid remains intact and associated with the carrier, and whether the formulation retains biological potency. Stability should be considered under the intended storage conditions, not inferred solely from a favorable appearance immediately after drying. These are study-design considerations informed by the review’s focus; they are not a standardized assay panel or prescribed protocol reported by the authors.

The review’s comparison of platforms also encourages matching process to product requirements. A method suited to a particular scale, formulation, or administration route may not be suitable for another. Selection should therefore be guided by the desired solid form, the cargo and LNP composition, process feasibility, and performance after reconstitution. Direct comparisons using consistent measurements are valuable when choosing between methods, because differences in test conditions can otherwise make results difficult to interpret.

Protocol Parameters

• Literature-backed process scope: The review discusses freeze-drying and alternative methods, including spin-freezing-based continuous freeze-drying, thin-film freeze-drying, spray freeze-drying, spray drying, and alcohol dilution freeze-drying. It does not establish one universal cycle or set of numerical operating conditions for all nucleic acid-LNPs.
• Workflow recommendation, not a paper-prescribed recipe: Set process conditions for the specific cargo and LNP formulation, and document the drying and reconstitution steps so that product performance can be compared across conditions.
• Evaluation recommendation, not a reported common standard: Assess particle properties, nucleic acid integrity or association, and biological potency after reconstitution and during storage. Interpret each measure alongside the intended product use.

Core Findings and Why They Matter

The review’s key practical finding is that drying is a promising stability strategy, but not a guarantee of stability. Freeze-drying is a major focus because it is an established way to create dried products, yet the process must preserve the functional relationship between the nucleic acid and its lipid carrier. A material that appears physically intact is not necessarily a potent delivery system; biological function after reconstitution remains central to evaluating success.

A second finding is that the field has more than one process option. The authors discuss alternatives that may offer different possibilities for continuous processing, particle formation, or product handling. Their inclusion broadens the development conversation beyond adapting a conventional freeze-drying cycle. It does not, however, establish that any alternative has already solved all stability or scale-up challenges. Process choice remains a formulation-specific decision.

Third, the article makes payload structure an explicit part of stability reasoning. Insights from mRNA-LNPs may inform work on other nucleic acid-LNPs, but differences among RNA and DNA structures mean that transfer should be tested rather than presumed. This point is relevant to emerging modalities: a drying strategy should be evaluated against the specific cargo’s integrity and the final particle’s delivery function. Collectively, the review positions solid-form development as a balance among storage stability, retained potency, process suitability, and intended administration route.

Comparison with Existing Internal Articles

The internal article Potassium Phosphate Monobasic: Technical Use in Biological Buffers addresses a different part of experimental practice: using KH2PO4 in aqueous buffer preparation for biochemical assays and related workflows. That discussion is useful when planning pH-controlled assay conditions, but it does not evaluate LNP drying, cargo protection, or solid-state stability. The two topics can sit within the same research program—one concerns assay environment and the other product processing—without implying that phosphate buffer is a drying stabilizer.

Limitations and Transferability

Because this is a review, its conclusions depend on the underlying studies, which may differ in LNP composition, cargo, drying process, storage conditions, and analytical methods. The supplied review summary does not provide a single standardized parameter set or a direct ranking of all technologies. Readers should consult the full article and relevant primary studies before translating a reported approach into a formulation or manufacturing workflow.

Transferability is another constraint. A method that works for one mRNA-LNP cannot automatically be assumed to work for a different sequence, particle composition, or nucleic acid class. Nor does improved storage stability alone establish clinical equivalence: the dried product must also be recoverable and retain the biological activity required for its intended use. The review’s broad comparison is therefore most valuable as a map of design questions and candidate approaches, rather than as a ready-made product recipe.

Finally, feasibility depends on the target use. Process and product requirements may differ with the desired route of administration and production context. The alternatives surveyed by the authors represent opportunities for further development, not proof that every method is suitable for every application. Researchers should distinguish promising process concepts from validated performance for a particular formulation.

Research Support Resources

Why this cross-domain matters, maturity, and limitations

Buffer preparation is adjacent to LNP research because assays may require controlled aqueous conditions, but buffer reagents should not be taken as evidence of improved dried-particle stability. For routine buffer preparation for biological assays, Potassium phosphate monobasic (KH2PO4; SKU B7291) can serve as an aqueous pH-control reagent, including as an enzyme assay buffer component or cell culture buffer reagent where the protocol calls for phosphate. Its use does not replace formulation-specific drying and potency studies.